JACK FACUNDUS: Open Payments
NPI 1376092809 · LONGWOOD, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,256 in 11 payments from 10 companies in 2025. Trend: 2023 $564 · 2024 $1,265 · 2025 $1,256
Food & beverage: $1,256
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $242 |
| Medtronic, Inc. | 1 | $146 |
| Gilead Sciences, Inc. | 1 | $130 |
| Neurocrine BioSciences, Inc. | 1 | $125 |
| Amgen Inc. | 1 | $117 |
| AstraZeneca Pharmaceuticals LP | 1 | $117 |
| E.R. Squibb & Sons, L.L.C. | 1 | $114 |
| Teva Pharmaceuticals USA, Inc. | 1 | $100 |
| ABIOMED | 1 | $96 |
| GENZYME CORPORATION | 1 | $68 |
Products named: CAPLYTA, SYMPLICITY G3, Livdelzi, INGREZZA, REPATHA, AIRSUPRA, COBENFY, FABRAZYME.
Industry payments across FL — which companies pay providers there.
